Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 24;10:12405. doi: 10.1038/s41598-020-69182-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Cytokine expression in MOG-reactive central memory cells (CMCs) from MOG-AAD patients at the time of relapse and remission: PBMCs were stimulated and cultured with 10 μg/ml of MOG peptides (p1-20, p35-55, p119-130, p181-195 and p186-200) and cocktail of myelin peptides (Myelin Phospholipid Protein 139–154, Myelin Basic Protein (MBP) 13–32, MBP 111–129 and MBP 146–170) for 7 days followed by staining with antibodies and flow cytometry as described in Materials and Methods. Data was analyzed using Flowjo vX.0.7 and the graphs were made using GraphPadPrism version 8.4.2 (464) A Percentage of IL17+producing CMCs (CD4+CCR7+CD45RA−, IL17+). B Percentage of IFNγ+producing CMCs (CD4+CCR7+CD45RA−,IFNγ+). C Percentage of IL17+ and IFNγ+ producing CMCs (CD4+CCR7+CD45RA−,IL17+,IFNγ+). Relapse n = 9, Remission n = 6 D CMCs (CD4+CCR7+CD45RA–), CMC IL17+ (CD4+CCR7+CD45RA−,IL17 +), CMC IFNγ+ (CD4+CCR7+CD45RA−, IFNγ+), CMC++ (CD4+CCR7+CD45RA−,IL17+, IFNγ+) analysis from a single pediatric MOG-AAD patient#1 with longitudinal samples, (1) Rm (remission, MOG-AAD#1.2), (2) PR (pre-relapse, MOG-AAD#1.3), (3) R (relapse, MOG-AAD#1.4) and (4) Rm/S (remission treated with steroid, MOG-AAD#1.5).